ArticleJournal of applied clinical medical physics2026
SRS/SBRT commissioning process with a hybrid beam data model in new preconfigured CyberKnife system.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA new preconfigured CyberKnife system was introduced to improve the SRS/SBRT commissioning efficiency. The vendor provides a reference beam data set, termed "beam data model (BDM)", and recommends its validation and combination with measurement data to develop a hybrid beam data model (h-BDM). However, the validation method by the user and the clinical acceptability with the h-BDM has not been established. PURPOSE: This study reports the first clinical validation of the BDM and aims to demonstrate the SRS/SBRT commissioning process with the h-BDM is clinically acceptable.
methodsThe BDM was validated by comparing with the measurements of tissue phantom ratios (TPRs), off-center ratios (OCRs), and output factors (OFs) for fixed and Iris collimators and MLC in CyberKnife S7 system. Dose difference (DD) and distance-to-agreement (DTA) between BDM and measurement data were assessed against predefined thresholds: DDs of 1.0% for TPRs; DDs of 1.0% at d
resultsDifferences between the BDM and measurement exceeded the specific thresholds for the OCRs with three largest MLC field sizes. In the single-beam validation, dose differences between measurements and calculations with h-BDM were within 2.0% for field sizes of > 10.0 mm, except up to 3.0% at 140 mm depth with MLC, and within 5.0% for field sizes of ≤10.0 mm. In PSQA with the h-BDMs, the point dose differences were within 3.0% and the γ pass rates (2%/2 mm and 3%/1 mm) were > 95.0% for all SRS/SBRT plans. The single-beam validation and PSQA results of the h-BDM were comparable to those of the conventional m-BDM.
conclusionsThe SRS/SBRT commissioning process with the proposed h-BDM provides a new clinically acceptable framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.